Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

589 ARTÍCULOS , VIENDO DEL 31 AL 45

Peptidylarginine Deiminase and Alzheimer's Disease

Wang L, Chen H, Tang J, Guo Z, Wang Y.

J Alzheimers Dis. 2022;85(2):473-484. doi: 10.3233/JAD-215302.

A(2A) Adenosine Receptor Antagonists in Neurodegenerative Diseases

Merighi S, Borea PA, Varani K, Vincenzi F, Jacobson KA, Gessi S.

Curr Med Chem. 2022;29(24):4138-4151. doi: 10.2174/0929867328666211129122550.

Amylin Pharmacology in Alzheimer's Disease Pathogenesis and Treatment

Corrigan RR, Piontkivska H, Casadesus G.

Curr Neuropharmacol. 2022;20(10):1894-1907. doi: 10.2174/1570159X19666211201093147.

BACE1: A Key Regulator in Alzheimer's Disease Progression and Current Development of its Inhibitors

Patel S, Bansoad AV, Singh R, Khatik GL.

Curr Neuropharmacol. 2022;20(6):1174-1193. doi: 10.2174/1570159X19666211201094031.

Machine Learning in Neuro-Oncology, Epilepsy, Alzheimer's Disease, and Schizophrenia

English M, Kumar C, Ditterline BL, Drazin D, Dietz N.

Acta Neurochir Suppl. 2022;134:349-361. doi: 10.1007/978-3-030-85292-4_39.

Role of Fyn Kinase Inhibitors in Switching Neuroinflammatory Pathways

Marotta G, Basagni F, Rosini M, Minarini A.

Curr Med Chem. 2022;29(27):4738-4755. doi: 10.2174/0929867329666211221153719.

Synthesis and inhibitory activities of inhibitors for the treatment of Alzheimer's disease

Zhou S, Huang G.

Chem Biol Drug Des. 2022 May;99(5):727-735. doi: 10.1111/cbdd.14016. Epub 2022 Feb 10.

Comprehensive Review on Neuro-degenerative Type 3 DM

Chandarana CV, Roy S.

Curr Diabetes Rev. 2022;18(8):e131221198790. doi: 10.2174/1573399818666211213103624.

Therapeutic Potential of Ferulic Acid in Alzheimer's Disease

Turkez H, Arslan ME, Barboza JN, Kahraman CY, de Sousa DP, Mardinoğlu A.

Curr Drug Deliv. 2022;19(8):860-873. doi: 10.2174/1567201819666211228153801.

Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease

Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O, Camps L, Swart EL, Kalisvaart K, Schoonenboom N, Lemstra E, Scheltens P, Cohen A, van Gerven J, Groeneveld GJ.

Br J Clin Pharmacol. 2022 Jun;88(6):2814-2829. doi: 10.1111/bcp.15206. Epub 2022 Jan 26.

The role of brain-derived neurotrophic factor and the neurotrophin receptor p75NTR in age-related brain atrophy and the transition to Alzheimer's disease

Cade S, Zhou XF, Bobrovskaya L.

Rev Neurosci. 2022 Jan 5;33(5):515-529. doi: 10.1515/revneuro-2021-0111. Print 2022 Jul 26.

Imidazole: Multi-targeted Therapeutic Leads for the Management of Alzheimer's Disease

Dhingra AK, Chopra B, Jain A, Chaudhary J.

Mini Rev Med Chem. 2022;22(10):1352-1373. doi: 10.2174/1389557522666220104152141.

Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease

Pons V, Rivest S.

Pharmacol Rev. 2022 Jan;74(1):1-17. doi: 10.1124/pharmrev.121.000400.

Mechanistic and therapeutic implications of EphA-4 receptor tyrosine kinase in the pathogenesis of Alzheimer's disease

Ganguly D, Thomas JA, Ali A, Kumar R.

Eur J Neurosci. 2022 Nov;56(9):5532-5546. doi: 10.1111/ejn.15591. Epub 2022 Jan 13.

The role of serotonin within the microbiota-gut-brain axis in the development of Alzheimer's disease: A narrative review

Aaldijk E, Vermeiren Y.

Ageing Res Rev. 2022 Mar;75:101556. doi: 10.1016/j.arr.2021.101556. Epub 2022 Jan 3.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias